On‐target/off‐tumour toxicity becomes a major hindrance of CSCs‐targeted CAR‐T therapy, because in normal cells, some CSCs markers are found, such as CD133 expressed in normal neural stem cells or ALDH expressed in hematopoietic stem cells.62, 63. This evidence concerns the gene PROM1 and neoplasm.